



Domains within RbpA Serve Specific Functional Roles That Regulate the Expression of Distinct Mycobacterial Gene Subsets

Jerome Prusa,^a Drake Jensen,^b Gustavo Santiago-Collazo,^a Steven S. Pope,^a Ashley L. Garner,^a Justin J. Miller,^a Ana Ruiz Manzano,^b Eric A. Galburt,^b Christina L. Stallings^a

^aDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA

^bDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri, USA

ABSTRACT The RNA polymerase (RNAP) binding protein A (RbpA) contributes to the formation of stable RNAP-promoter open complexes (RP_o) and is essential for viability in mycobacteria. Four domains have been identified in the RbpA protein, i.e., an N-terminal tail (NTT) that interacts with RNAP β' and σ subunits, a core domain (CD) that contacts the RNAP β' subunit, a basic linker (BL) that binds DNA, and a σ -interaction domain (SID) that binds group I and group II σ factors. Limited *in vivo* studies have been performed in mycobacteria, however, and how individual structural domains of RbpA contribute to RbpA function and mycobacterial gene expression remains mostly unknown. We investigated the roles of the RbpA structural domains in mycobacteria using a panel of *rbpA* mutants that target individual RbpA domains. The function of each RbpA domain was required for *Mycobacterium tuberculosis* viability and optimal growth in *Mycobacterium smegmatis*. We determined that the RbpA SID is both necessary and sufficient for RbpA interaction with the RNAP, indicating that the primary functions of the NTT and CD are not solely association with the RNAP. We show that the RbpA BL and SID are required for RP_o stabilization *in vitro*, while the NTT and CD antagonize this activity. Finally, RNA-sequencing analyses suggest that the NTT and CD broadly activate gene expression, whereas the BL and SID activate or repress gene expression in a gene-dependent manner for a subset of mycobacterial genes. Our findings highlight specific outcomes for the activities of the individual functional domains in RbpA.

IMPORTANCE *Mycobacterium tuberculosis* is the causative agent of tuberculosis and continues to be the most lethal infectious disease worldwide. Improved molecular understanding of the essential proteins involved in *M. tuberculosis* transcription, such as RbpA, could provide targets for much needed future therapeutic agents aimed at combatting this pathogen. In this study, we expand our understanding of RbpA by identifying the RbpA structural domains responsible for the interaction of RbpA with the RNAP and the effects of RbpA on transcription initiation and gene expression. These experiments expand our knowledge of RbpA while also broadening our understanding of bacterial transcription in general.

KEYWORDS *Mycobacterium*, RNA polymerases, RbpA, eubacteria, transcription, transcriptional regulation

Progress toward the World Health Organization (WHO) goal of eradicating *Mycobacterium tuberculosis* continues to be hampered by the estimated 480,000 new cases of multidrug-resistant *M. tuberculosis* infections among the overall 10.1 million new cases of tuberculosis worldwide in 2016 (1). Strategies for *M. tuberculosis* eradication include the development of novel therapies, which is aided by the identification of druggable targets. Bacterial transcription is carried out by the RNA polymerase (RNAP)

Received 15 November 2017 Accepted 18 April 2018

Accepted manuscript posted online 23 April 2018

Citation Prusa J, Jensen D, Santiago-Collazo G, Pope SS, Garner AL, Miller JJ, Ruiz Manzano A, Galburt EA, Stallings CL. 2018. Domains within RbpA serve specific functional roles that regulate the expression of distinct mycobacterial gene subsets. *J Bacteriol* 200:e00690-17. <https://doi.org/10.1128/JB.00690-17>.

Editor Tina M. Henkin, Ohio State University

Copyright © 2018 American Society for Microbiology. All Rights Reserved.

Address correspondence to Christina L. Stallings, stallings@wustl.edu.

and has been successfully targeted using rifampin, which remains a cornerstone of therapy for *M. tuberculosis* patients (2, 3). In addition to the subunits that constitute the RNAP holoenzyme in all bacteria (two α subunits and β , β' , ω , and σ subunits), mycobacteria also require two additional essential proteins, RNAP binding protein A (RbpA) and CarD, to form stable transcription initiation complexes (4–7). Unlike *Escherichia coli*, which has been used to define the events of bacterial transcription initiation, mycobacteria are unable to irreversibly form stable RNAP-promoter open complexes (RP_o) and require both RbpA and CarD to reach RP_o stability comparable to that of *E. coli* (4, 7, 8), which could explain the essentiality of these proteins (9–11). Both CarD and RbpA have also been shown to affect the sensitivity of mycobacteria to rifampin (12, 13). Therefore, improving our understanding of these transcription factors could provide an avenue to future therapies targeting CarD or RbpA while improving the efficacy of currently approved drugs.

RbpA was discovered in *Streptomyces coelicolor* as a protein that coimmunoprecipitates with the RNAP and is unique to the *Actinobacteria* phylum (14). RbpA consists of a central core domain (CD) flanked by an unstructured 26-amino-acid N-terminal tail (NTT) and a C-terminal σ -interaction domain (SID) linked to the CD by a 15-amino-acid basic linker (BL) (6, 11, 15, 16). The RbpA SID forms a stable binary complex with group I (σ^A in *M. tuberculosis*) and certain group II (σ^B in *M. tuberculosis*) σ factors (6, 14–16). Bacterial two-hybrid experiments in *S. coelicolor* showed that mutating the R88 residue within the RbpA SID to an alanine significantly weakened the interaction between *S. coelicolor* RbpA and the housekeeping σ^{HrdB} (15), highlighting the importance of this residue in the interaction. Based on structural studies, the BL makes electrostatic contacts with the DNA phosphate backbone of the nontemplate strand upstream of the –10 promoter element in the RP_o conformation, the CD is positioned near the RNAP β' zinc binding domain, and the NTT threads into the RNAP active site cleft between the β' zinc binding domain and the σ^A_4 domain (6, 16, 17). In support of a functional role for the BL, fluorescence anisotropy experiments showed that addition of *M. tuberculosis* RbpA to *Mycobacterium bovis* RNAP- σ^A holoenzyme in the presence of *M. tuberculosis* CarD decreased the dissociation constant (K_d) of RNAP binding to a *vapB10* promoter template and an R79A mutation in the *M. tuberculosis* RbpA BL abolished the RbpA-mediated increases in RNAP affinity for the *vapB10* promoter (16).

Most characterization of RbpA has been performed *in vitro*, and there have been only limited studies of how the domains of RbpA contribute to gene regulation in mycobacteria. In a recent study using *Mycobacterium smegmatis*, an R79A mutation in the RbpA BL and deletion of the NTT and CD resulted in slower growth of the bacteria (6). Herein, we expand on that work and compare the roles of each RbpA domain, both *in vitro* and *in vivo*, to show that only the SID is required for association with the RNAP and the activities of different domains affect the expression of distinct gene sets in the bacteria.

RESULTS

Individual RbpA structural domains are important for mycobacterial growth and viability. To distinguish the roles of the RbpA structural domains in mycobacteria (Fig. 1A), we first engineered merodiploid strains of *M. tuberculosis* and *M. smegmatis* that expressed *rbpA*_{Mtb} at the chromosomal *attB* site. The *M. smegmatis* and *M. tuberculosis* RbpA proteins are 92% identical. Expression of *rbpA*_{Mtb} at the *attB* site allowed deletion of the endogenous *rbpA* gene in both *M. tuberculosis* and *M. smegmatis*, demonstrating that the RbpA protein from *M. tuberculosis* can substitute for the *M. smegmatis* RbpA protein to support viability. We then attempted to replace the *rbpA*_{Mtb} gene at the *attB* site in *M. tuberculosis* and *M. smegmatis* with alleles encoding RbpA_{Mtb}^{R79A}, RbpA_{Mtb}^{R88A}, RbpA_{Mtb}^{1–71}, or RbpA_{Mtb}^{72–111}, using a previously described gene-swapping method (13, 18). The R79A mutation is within the BL and should disrupt DNA binding, the R88A mutation in the SID has been shown to weaken the affinity of RbpA for σ , the position 1 to 71 RbpA fragment is deleted for the BL and SID, and the position 72 to 111 RbpA fragment is deleted for the NTT and CD (Fig. 1) (11, 15, 16).




FIG 1 Multiple RbpA structural domains are important for mycobacterial growth and viability. (A) Diagram showing that *M. tuberculosis* RbpA is composed of an N-terminal tail (NTT) (amino acids 1 to 25), a core domain (CD) (amino acids 26 to 66), a basic linker (BL) (amino acids 67 to 80), and a σ -interaction domain (SID) (amino acids 81 to 111). (B) Table of *M. tuberculosis* and *M. smegmatis* strains engineered or determined to be nonviable with replacement of the RbpA_{Mtb}^{WT} expression cassette with a cassette expressing RbpA_{Mtb}^{R79A}, RbpA_{Mtb}^{R88A}, RbpA_{Mtb}¹⁻⁷¹, or RbpA_{Mtb}⁷²⁻¹¹¹. An empty expression cassette was transformed as a negative control, while replacement of RbpA_{Mtb}^{WT} with RbpA_{Mtb}^{WT} was used as a positive control. (C) Growth curves of *M. smegmatis* expressing RbpA_{Mtb}^{WT}, RbpA_{Mtb}^{R79A}, RbpA_{Mtb}^{R88A}, or RbpA_{Mtb}⁷²⁻¹¹¹, with nine replicates for each strain. (D) *M. smegmatis* doubling times calculated from the growth curves in panel C. Results are plotted as means \pm standard deviations. Statistical significance was analyzed by analysis of variance (ANOVA) and Tukey's multiple-comparison test. *, $P \leq 0.05$; **, $P \leq 0.01$; ***, $P \leq 0.001$. All comparisons were included in the analysis, but only statistically significant differences are indicated in the figure. (E) Lysates from *M. smegmatis* $\Delta rbpA$ *attB::tet-rbpA* expressing RbpA_{Mtb}^{WT}-FLAG (lane 1), RbpA_{Mtb}^{R79A}-FLAG (lane 2), RbpA_{Mtb}^{R88A}-FLAG (lane 3), or RbpA_{Mtb}⁷²⁻¹¹¹-FLAG (lane 4), analyzed with monoclonal antibodies specific for either RNAP β or FLAG. (F) Graphical representation of RbpA stability as the ratio of RbpA molecules per RNAP β , showing the means \pm standard errors of the means of three replicates. Statistical significance was analyzed by ANOVA and Tukey's multiple-comparison test. *, $P \leq 0.05$; ns, not significant.

Using the gene-swapping approach, we found that none of the RbpA mutants could support viability in *M. tuberculosis* (Fig. 1B), demonstrating that *M. tuberculosis* is highly sensitive to any kind of disruption in RbpA function. In contrast, all of the mutant *rbpA* alleles except that encoding RbpA_{Mtb}¹⁻⁷¹ supported viability of *M. smegmatis*, thus

providing us with a genetic system to study *M. tuberculosis* RbpA *in vivo* by using *M. smegmatis* strains expressing RbpA_{Mtb}^{WT}, RbpA_{Mtb}^{R79A}, RbpA_{Mtb}^{R88A}, and RbpA_{Mtb}⁷²⁻¹¹¹. The inability to obtain strains expressing the RbpA_{Mtb}¹⁻⁷¹ allele as the only *rbpA* allele demonstrated that the RbpA BL and SID are required for viability in mycobacteria.

To determine how each of these mutations in RbpA affected mycobacterial growth, the doubling times of *M. smegmatis* strains expressing the wild type (WT), RbpA_{Mtb}^{WT}, or mutant RbpA_{Mtb}^{R79A}, RbpA_{Mtb}^{R88A}, or RbpA_{Mtb}⁷²⁻¹¹¹ were measured (Fig. 1C and D). The doubling times of the RbpA_{Mtb}^{R79A} (4.3 h) and RbpA_{Mtb}^{R88A} (4.4 h) strains were significantly longer than that of the RbpA_{Mtb}^{WT} strain (3.2 h), indicating that the functions performed by the RbpA BL and SID are required for optimal *M. smegmatis* growth (Fig. 1D). Although the growth rate of the RbpA_{Mtb}⁷²⁻¹¹¹ (3.9 h) strain trended lower than that of the RbpA_{Mtb}^{WT} strain, this difference was not statistically significant, indicating that loss of the RbpA NTT and CD has only a mild effect on *M. smegmatis* growth.

To determine whether the mutations in RbpA affected the RbpA protein levels in *M. smegmatis*, we engineered *M. smegmatis* strains that expressed the C-terminally FLAG-tagged RbpA proteins RbpA_{Mtb}^{WT}-FLAG, RbpA_{Mtb}^{R79A}-FLAG, RbpA_{Mtb}^{R88A}-FLAG, and RbpA_{Mtb}⁷²⁻¹¹¹-FLAG as the only copy of the *rbpA* product and we measured the levels of RbpA_{Mtb}^{WT}-FLAG, RbpA_{Mtb}^{R79A}-FLAG, RbpA_{Mtb}^{R88A}-FLAG, and RbpA_{Mtb}⁷²⁻¹¹¹-FLAG proteins in cell lysates by Western blot analysis (Fig. 1E). The levels of RbpA_{Mtb}^{R88A}-FLAG protein were significantly lower than the levels of RbpA_{Mtb}^{WT}-FLAG. Therefore, the slower growth of the *M. smegmatis* strain expressing RbpA_{Mtb}^{R88A} could in part be a result of lower levels of RbpA protein. The levels of RbpA_{Mtb}⁷²⁻¹¹¹-FLAG protein were also significantly lower in cell lysates, compared to the levels of RbpA_{Mtb}^{WT}-FLAG. However, we found that this decrease in band intensity was due to issues with the detection of RbpA_{Mtb}⁷²⁻¹¹¹-FLAG with the anti-FLAG antibody. Therefore, it is unclear whether deletion of the RbpA NTT and CD decreases the levels of RbpA_{Mtb}⁷²⁻¹¹¹-FLAG in cell lysates.

The RbpA SID is necessary and sufficient for association with RNAP. Structural studies indicate that RbpA engages in four different macromolecular interactions in mycobacterial RNAP-promoter initiation complexes, i.e., (i) the RbpA NTT binding to RNAP β' and σ , (ii) the RbpA CD binding to RNAP β' , (iii) the RbpA BL binding to DNA, and (iv) the RbpA SID binding to σ (6, 11, 16); however, it is not known which of these interactions are required for the association of RbpA with the RNAP. To address this gap in knowledge, we performed coimmunoprecipitation experiments analyzing the amounts of σ^A , σ^B , and RNAP β subunit that coimmunoprecipitated with the RbpA-FLAG-tagged proteins (Fig. 2). The levels of σ^A and σ^B coimmunoprecipitated with RbpA_{Mtb}^{R88A}-FLAG were dramatically reduced, compared to those coimmunoprecipitated with RbpA_{Mtb}^{WT}-FLAG (Fig. 2A, B, and C), as expected based on the importance of R88 for σ binding (15). In addition to the decreases in σ^A and σ^B levels, the levels of RNAP β coimmunoprecipitated with RbpA_{Mtb}^{R88A}-FLAG were significantly reduced (Fig. 2A and D). In crystallographic studies, the R88 in the RbpA SID is not positioned to bind directly to the core RNAP subunits; therefore, we conclude that the reduced β coimmunoprecipitated with RbpA_{Mtb}^{R88A}-FLAG is due to the reduced RbpA- σ interaction. This indicates that the interaction between the RbpA SID and the σ subunit is the primary determinant of the association of RbpA with the RNAP. In contrast, deletion of the NTT and CD (RbpA_{Mtb}⁷²⁻¹¹¹) did not decrease the amounts of RNAP β , σ^A , or σ^B associated with RbpA. Therefore, despite the observations that the CD was positioned to interact with RNAP β' and the NTT was positioned to interact with RNAP β' and σ (6, 17), these interactions are not necessary for association with RNAP. Notably, although the levels of RNAP β , σ^A , and σ^B coimmunoprecipitated per molecule of RbpA_{Mtb}⁷²⁻¹¹¹ appear to be increased in Fig. 2, we found that the differences were due to lower levels of RbpA_{Mtb}⁷²⁻¹¹¹ detection by Western blot analysis (data not shown). RbpA_{Mtb}^{R79A}-FLAG coimmunoprecipitated similar levels of β and σ^A , compared to RbpA_{Mtb}^{WT}-FLAG. Coimmunoprecipitated levels of σ^B trended higher with RbpA_{Mtb}^{R79A}-




FIG 2 The RbpA SID is necessary and sufficient for the association of RbpA with the RNAP. (A) Western blot analysis of lysates immunoprecipitated for FLAG-tagged RbpA. Monoclonal antibodies specific for FLAG were used to detect RbpA_{Mtb}-FLAG protein variants (bottom row). RNAP β coimmunoprecipitated by the FLAG-tagged RbpA constructs was detected with a monoclonal antibody specific for RNAP β, and both σ^A and σ^B were detected using a monoclonal antibody specific for a shared epitope in *E. coli* σ⁷⁰. (B to D) Amounts of σ^A (B), σ^B (C), and RNAP β (D) coimmunoprecipitated by RbpA, based on band intensity, and expressed as the ratio of σ^A, σ^B, or RNAP β to RbpA, with eight replicates for each strain. Results are shown as means ± standard deviations. Statistical significance was determined by one-way ANOVA and Kruskal-Wallis multiple-comparison test. *, $P \leq 0.05$; **, $P \leq 0.01$.

FLAG but were not statistically significantly different from those observed with RbpA_{Mtb}^{WT-FLAG} (Fig. 2). Collectively, our data show that the RbpA SID is both necessary and sufficient for interaction with RNAP.

RbpA mutants exhibit distinct kinetic phenotypes on the pathway to RP_o formation. RbpA has been proposed to accelerate a forward kinetic step in the formation of RP_o, resulting in more stable RP_o at equilibrium (6, 7). A real-time fluorescence assay (7) was used to determine the effects of RbpA mutants on RP_o formation by the *M. tuberculosis* RNAP. Briefly, a Cy3 label was incorporated onto the +2 dT nucleotide, with respect to the +1 transcription start site, of the nontemplate strand of the *M. tuberculosis* rRNA *rrnAP3* promoter (19). The Cy3 label is positioned within the transcription bubble such that, upon opening of the promoter DNA, a 2-fold fluorescence enhancement is observed (20); this allows quantitation of the kinetics of RP_o equilibration, by monitoring the change in fluorescence as a function of time, and the stability of RP_o, by using the equilibrium fluorescence value (4, 7, 21). Incubating RbpA_{Mtb}^{WT} at a saturating concentration (2 μM) with 35 nM *M. tuberculosis* RNAP-σ^A holoenzyme and the Cy3-labeled *rrnAP3* promoter resulted in a greater amount of RP_o at equilibrium than observed with RNAP-σ^A holoenzyme and the *rrnAP3* promoter alone (Fig. 3A), consistent with the known role of RbpA in stabilizing the otherwise unstable mycobacterial RNAP open complex (6, 7). When the same concentrations of




FIG 3 RbpA mutants exhibit distinct effects on RP_o formation. (A) Fluorescence fold changes, compared to DNA alone, which were used to monitor RP_o formation and stability in real time, using fixed amounts of *M. tuberculosis* RNAP (35 nM), Cy3-labeled (+2 thymine nontemplate strand) *M. tuberculosis* *rrnAP3* promoter DNA (1 nM), and RbpA (2 μ M). Time courses are shown as an average of at least 5 replicates. (B) Total fluorescent fold changes, normalized to RNAP- σ^A -*rrnAP3* alone, for all RbpA constructs. (C) $t_{1/2}$ values, calculated as the time required to reach one-half of the final fluorescence intensity, for each sample. For panels B and C, means \pm standard errors of the means are plotted. Statistical significance was analyzed by ANOVA and Tukey's multiple-comparison test. *, $P \leq 0.05$; **, $P \leq 0.01$; ****, $P \leq 0.0001$; ns, not significant. Only comparisons between RbpA^{WT} and each of the RbpA mutant constructs are shown in the figure.

RbpA_{Mtb}^{R79A} and RbpA_{Mtb}^{R88A} were added, no enhancement of the amount of RP_o at equilibrium over RNAP- σ^A holoenzyme and the *rrnAP3* promoter alone was observed (Fig. 3A and B), demonstrating the importance of these residues. For a qualitative description of the kinetics, we calculated $t_{1/2}$ values (the time required to reach the midpoint of the final equilibrium fluorescence). Interestingly, these mutants exhibited approximately 3-fold faster kinetics (RbpA_{Mtb}^{R79A} $t_{1/2}$ of 14.8 ± 1.1 s and RbpA_{Mtb}^{R88A} $t_{1/2}$ of 16.4 ± 1.1 s), compared with the RNAP- σ^A holoenzyme and the *rrnAP3* promoter alone ($t_{1/2}$ of 43 ± 2 s) (Fig. 3C). The finding of faster kinetics accompanied by no change in the equilibrium fluorescence value suggests that these mutants retain the ability to stabilize the transition state on the pathway to RP_o but have lost the ability to stabilize RP_o itself. This behavior is analogous to the classic model for enzyme activity (22), in which the transformation of substrate to product is accelerated without changes in the final equilibrium between the two states. In this scenario, the mutant RbpA proteins may increase the rate of opening and the rate of closing equally, such that the ratio of rates remains constant. These results suggest that the interactions between RbpA and both the promoter DNA (R79) and σ factor (R88) are essential for RP_o stabilization and that RbpA is still capable of catalyzing promoter opening even in the presence of these mutations.

To further investigate the domain requirements for RP_o stabilization, we repeated the experiments described above with $RbpA_{Mtb}^{1-71}$ (containing the NTT and CD) and $RbpA_{Mtb}^{26-71}$ (containing the CD only), and we observed minimal enhancement in RP_o stability (Fig. 3A and B) and an identical rate of RP_o equilibration ($t_{1/2}$ of 42 ± 3 s), relative to the RNAP- σ^A holoenzyme and the *rrnAP3* promoter alone (Fig. 3A and C), indicating that the NTT and CD are unable to affect RP_o stability on their own. Conversely, $RbpA_{Mtb}^{72-111}$ showed the greatest amount of RP_o at equilibrium, even higher than that of $RbpA_{Mtb}^{WT}$ (Fig. 3A and B), with kinetics ($t_{1/2}$ of 7.8 ± 0.9 s) similar to those of $RbpA_{Mtb}^{WT}$ ($t_{1/2}$ of 6.9 ± 0.5 s) (Fig. 3C). The finding that $RbpA_{Mtb}^{72-111}$ exhibits similar kinetics but a greater amount of RP_o at equilibrium, compared with $RbpA_{Mtb}^{WT}$, raises the possibility that the NTT and CD negatively affect RbpA activity under these conditions. To determine whether it was the NTT and/or the CD that antagonized RbpA-mediated RP_o stabilization, we assayed an RbpA protein with deletion of just the NTT ($RbpA_{Mtb}^{26-111}$). $RbpA_{Mtb}^{26-111}$ yielded a greater fold change in fluorescence than did $RbpA_{Mtb}^{WT}$ but smaller change than did $RbpA_{Mtb}^{72-111}$ (Fig. 3A and B), suggesting that both the CD and NTT are responsible for the antagonistic effect on RbpA-dependent RP_o stability. $RbpA_{Mtb}^{26-111}$ exhibited approximately 2-fold slower kinetics of RP_o equilibration ($t_{1/2}$ of 17.6 ± 1.2 s) than did $RbpA_{Mtb}^{72-111}$ ($t_{1/2}$ of 7.8 ± 0.9 s) and $RbpA_{Mtb}^{WT}$ ($t_{1/2}$ of 6.9 ± 0.5 s) (Fig. 3A and C). One possibility consistent with this observation is that, in the presence of the rest of the domains, the NTT decreases the amount of RP_o at equilibrium by increasing a reverse rate leading toward the RNAP-promoter closed complex (RP_c). Importantly, performing these experiments with multiple RNAP concentrations suggests that the effect of each RbpA construct is limited by DNA-bound kinetic intermediates and not the rates of association and dissociation of RNAP to and from promoter DNA (see Fig. S1 in the supplemental material). Taken together, these results suggest that residues R79 and R88 are essential for RP_o stabilization and that the NTT and CD can inhibit RP_o formation.

Truncation of the RbpA NTT/CD and mutations in the RbpA BL and SID result in distinct gene expression changes in *M. smegmatis*. To determine how the individual RbpA domains contribute to gene expression, we performed RNA-sequencing (RNA-seq) experiments with cultures of *M. smegmatis* expressing $RbpA_{Mtb}^{R79A}$, $RbpA_{Mtb}^{R88A}$, $RbpA_{Mtb}^{72-111}$, or $RbpA_{Mtb}^{WT}$ (Table S1). The only previous analysis of this type focused on the gene expression profiles that resulted from deletion of the RbpA NTT and CD in *M. smegmatis*, but it did not investigate the roles of the other RbpA domains (6). Principal-component analysis (PCA) of the RNA-seq data was performed and provided a general overview of how gene expression patterns among the RbpA mutants clustered in relationship to each other. Three distinct sample clusters were apparent from the PCA results (Fig. 4A), indicating three different gene expression patterns. The first cluster included the three $RbpA_{Mtb}^{WT}$ replicates, the second cluster included the three $RbpA_{Mtb}^{72-111}$ replicates, and the third cluster included the replicates from both $RbpA_{Mtb}^{R79A}$ and $RbpA_{Mtb}^{R88A}$. The PCA results indicate that loss of the RbpA NTT/CD affects a gene subset that is different from the genes affected by mutations in the RbpA BL and SID. The number of genes significantly (adjusted *P* values of <0.05) upregulated or downregulated 2-fold in the RbpA mutants varied, with 766 genes being differentially expressed in $RbpA_{Mtb}^{72-111}$, compared to 199 genes in $RbpA_{Mtb}^{R79A}$ and 244 genes in $RbpA_{Mtb}^{R88A}$ (Fig. 4B; also see Table S2).

Consistent with the PCA results, there was significant overlap in upregulated and downregulated genes between the $RbpA_{Mtb}^{R79A}$ and $RbpA_{Mtb}^{R88A}$ strains (Fig. 4C and D and Table 1), indicating that the SID and BL perform functions that contribute to the expression of a common subset of *M. smegmatis* genes. Also consistent with the PCA results, the upregulated and downregulated genes in $RbpA_{Mtb}^{72-111}$ had little overlap with those in either $RbpA_{Mtb}^{R79A}$ or $RbpA_{Mtb}^{R88A}$ (Fig. 4C and D). Therefore, the number of shared downregulated or upregulated genes between $RbpA_{Mtb}^{72-111}$ and either $RbpA_{Mtb}^{R79A}$ or $RbpA_{Mtb}^{R88A}$ was underenriched (Table 1).

Given that RbpA stabilizes RNAP- σ^A -*rrnAP3* RP_o *in vitro* and the R79 and R88 residues are essential for this activity, it might be expected that the RbpA BL and SID cooperate




FIG 4 Truncation of the RbpA NTT/CD and mutations in the RbpA BL and SID result in distinct gene expression changes in *M. smegmatis*. (A) PCA results showing sample distances across two principal components (PC), generated using read counts of RNA collected from *M. smegmatis* expressing RbpA_{Mtb}^{WT}, RbpA_{Mtb}^{R79A}, RbpA_{Mtb}^{R88A}, or RbpA_{Mtb}⁷²⁻¹¹¹, mapped to the *M. smegmatis* mc²155 genome and normalized with regularized logarithmic transformation. Each point represents one of three replicates for RbpA_{Mtb}^{WT}, RbpA_{Mtb}^{R79A}, RbpA_{Mtb}^{R88A}, and RbpA_{Mtb}⁷²⁻¹¹¹. (B) Numbers of genes significantly (adjusted *P* values of ≤ 0.05) upregulated or downregulated 2-fold in *M. smegmatis* expressing RbpA_{Mtb}^{R79A}, RbpA_{Mtb}^{R88A}, or RbpA_{Mtb}⁷²⁻¹¹¹, relative to *M. smegmatis* expressing RbpA_{Mtb}^{WT}. FC, fold change. (C) Venn diagram showing overlap of the genes downregulated 2-fold (adjusted *P* values of ≤ 0.05) in *M. smegmatis* expressing RbpA_{Mtb}^{R79A}, RbpA_{Mtb}^{R88A}, or RbpA_{Mtb}⁷²⁻¹¹¹, relative to *M. smegmatis* expressing RbpA_{Mtb}^{WT}. (D) Venn diagram showing overlap of the genes upregulated 2-fold (adjusted *P* values of ≤ 0.05) in *M. smegmatis* expressing RbpA_{Mtb}^{R79A}, RbpA_{Mtb}^{R88A}, or RbpA_{Mtb}⁷²⁻¹¹¹, relative to *M. smegmatis* expressing RbpA_{Mtb}^{WT}. (E) qRT-PCR and RNA-seq log₂ fold changes for 16 genes in *M. smegmatis* expressing RbpA_{Mtb}^{R79A}, RbpA_{Mtb}^{R88A}, or RbpA_{Mtb}⁷²⁻¹¹¹, relative to *M. smegmatis* expressing RbpA_{Mtb}^{WT}. Transcript levels were normalized to an MS2 RNA spike-in control that was added at a constant level of 1 ng/1 billion cells. Means \pm standard errors of the means of three replicates are shown for each *M. smegmatis* strain.

to activate transcription from all promoters that RbpA regulates. Similarly, the ability of the NTT and CD to antagonize RbpA-mediated RP_o stabilization would lead to the hypothesis that expression from RbpA-regulated genes would be increased in their absence. However, this was not supported by the RNA-seq data, in which similar

TABLE 1 Overlap enrichment of differentially expressed genes in *M. smegmatis* strains expressing RbpA_{Mtb}^{R79A}, RbpA_{Mtb}^{R88A}, or RbpA_{Mtb}^{72-111a}

Overlap comparison	Hypergeometric <i>P</i> value	Fold enrichment
RbpA _{Mtb} ^{R79A} vs RbpA _{Mtb} ^{R88A} , upregulated	1.81E−11	+1.52
RbpA _{Mtb} ^{R79A} vs RbpA _{Mtb} ^{R88A} , downregulated	0.0003	+1.59
RbpA _{Mtb} ^{R79A} vs RbpA _{Mtb} ⁷²⁻¹¹¹ , upregulated	0.094	−1.22
RbpA _{Mtb} ^{R79A} vs RbpA _{Mtb} ⁷²⁻¹¹¹ , downregulated	1.63E−07	−2.03
RbpA _{Mtb} ^{R88A} vs RbpA _{Mtb} ⁷²⁻¹¹¹ , upregulated	0.001	−1.43
RbpA _{Mtb} ^{R88A} vs RbpA _{Mtb} ⁷²⁻¹¹¹ , downregulated	0.0005	−1.69

^aOverlap enrichment of differentially upregulated (log₂ fold change of >1.0; adjusted *P* value of <0.05) and differentially downregulated (log₂ fold change of <−1.0; adjusted *P* value of <0.05) genes for each possible comparison between RbpA_{Mtb}^{R79A}, RbpA_{Mtb}^{R88A}, and RbpA_{Mtb}⁷²⁻¹¹¹ was evaluated by calculating a hypergeometric *P* value for fold overenrichment (positive values in the fold enrichment column) or underenrichment (negative values in the fold enrichment column). Fold enrichment values were calculated by dividing the number of overlapping genes observed for each comparison by the number of overlapping genes expected when the null hypothesis of no enrichment was accepted for the same comparison. *P* values indicate the probability that the underenrichment or overenrichment in the overlap of differentially expressed genes of the two strains being compared would occur randomly. *P* values of <0.05 are statistically significant.

numbers of transcripts were upregulated and downregulated in each RbpA mutant (Fig. 4B). These data could mean that domains within RbpA can promote both activation and repression of gene expression. However, it is also possible that there was general downregulation or upregulation of gene expression in the RbpA mutants that we were unable to detect due to the addition of equal amounts of RNA from each strain into the sequencing reaction. To explore this possibility, we performed spike-in experiments (23) in which we isolated RNA from cultures of *M. smegmatis* expressing RbpA_{Mtb}^{R79A}, RbpA_{Mtb}^{R88A}, RbpA_{Mtb}⁷²⁻¹¹¹, or RbpA_{Mtb}^{WT} and added 1 ng of MS2 bacteriophage RNA (Roche) per 1 billion bacterial cells to the RNA samples. cDNA was generated for each sample, and quantitative reverse transcription-PCR (qRT-PCR) was performed to determine transcript levels for 16 *M. smegmatis* genes relative to MS2 RNA, which was used as a proxy to represent cell number. The 16 *M. smegmatis* genes analyzed included genes that were significantly upregulated or downregulated in RbpA mutants during RNA-seq experiments. When results were normalized to MS2 RNA levels, all 16 genes, including the genes considered highly upregulated in the RNA-seq analysis, were downregulated in RbpA_{Mtb}⁷²⁻¹¹¹ compared to RbpA_{Mtb}^{WT}, suggesting that overall transcript levels in RbpA_{Mtb}⁷²⁻¹¹¹ are decreased (Fig. 4E). Therefore, despite the findings that deletion of the NTT and CD had only a mild effect on the growth rate (Fig. 1C and D) and enhanced RP_o stabilization activity *in vitro* (Fig. 3A and B), the NTT and CD are required for WT levels of gene expression in *M. smegmatis*. In contrast, qRT-PCR results for the RbpA_{Mtb}^{R79A} and RbpA_{Mtb}^{R88A} mutants were similar to the RNA-seq results, indicating that RbpA_{Mtb}^{R79A} and RbpA_{Mtb}^{R88A} mutants do indeed lead to both upregulation and downregulation of gene expression. When we analyzed the genes that were most upregulated or downregulated with the RbpA_{Mtb}^{R79A} and RbpA_{Mtb}^{R88A} mutants, they fell into multiple diverse functional classes (Table S2), indicating that RbpA activity likely affects multiple cellular processes.

DISCUSSION

In this study, we investigated the functions of the individual RbpA structural domains to gain insight into the complex *in vivo* roles of RbpA. To study the roles of the RbpA NTT and CD, we truncated the N-terminal 71 amino acids of RbpA. The role of the RbpA BL was probed using a point mutation at R79, which has been implicated in the interaction between RbpA and DNA (16). Finally, we investigated the RbpA SID by using a point mutation at R88, which is one of the key residues needed for the interaction between RbpA and σ (15) but had yet to be studied in mycobacteria *in vivo*. We found that the function of each RbpA structural domain is required for *M. tuberculosis* viability and wild-type growth rates in *M. smegmatis* and disruption of the RbpA BL and SID functions causes a more severe growth defect than loss of the NTT and CD.

Our data indicate that *M. tuberculosis* has a more stringent requirement for RbpA activity, similar to what we observed for CarD (5, 13).

We determined that the RbpA SID interaction with σ is the only interaction required for the association of RbpA with the RNAP; the RbpA R88A substitution resulted in not only loss of the interactions with σ^A and σ^B but also almost complete loss of association with the core RNAP β subunit. In contrast, deletion of the NTT and CD did not negatively affect the association of RbpA with RNAP, suggesting that the RbpA NTT and CD serve functions distinct from interaction with RNAP. The RbpA R88A substitution also resulted in decreased RbpA protein levels. Previous studies investigating CarD mutants with altered affinities for the RNAP found that CarD protein levels correlated with CarD affinity for the RNAP (21). Our data showing that RbpA_{Mtb}^{R88A} has a lower affinity for the RNAP and is present in lower abundance in the cell supports a model in which RbpA protein levels are also affected by its ability to interact with the RNAP. CarD was shown to be a target of the Clp protease in *M. tuberculosis* and, similarly, RbpA levels were >2-fold higher in a *M. tuberculosis* strain lacking Clp protease subunits, suggesting that RbpA protein levels may also be regulated by the Clp protease (24).

Previous studies investigating the effect of RbpA on RP_o stability reported that R79 is required for RP_o stabilization, whereas both the NTT and CD are dispensable (6, 7). We have expanded on these findings by determining that the RbpA- σ interaction is required for enhanced RP_o stability and the NTT and CD antagonize this activity (Fig. 3). Furthermore, our results suggest that the effect of RbpA on the kinetics of RP_o equilibration can be differentiated from its effect on equilibrium levels of RP_o and that RbpA can affect both forward and reverse rates on the pathway to RP_o, at the concentrations tested. The similar effects of RbpA BL and SID mutations on RP_o stabilization (Fig. 3) mirror the significant overlap in the expression profiles of RbpA_{Mtb}^{R79A} and RbpA_{Mtb}^{R88A} (Fig. 4). In contrast, the truncation of NTT and CD, which affects RP_o stability differently than mutations in RbpA BL and CD, results in an expression profile significantly different from that of RbpA_{Mtb}^{R79A} and RbpA_{Mtb}^{R88A}.

We have found that RbpA_{Mtb}^{R79A} and RbpA_{Mtb}^{R88A} mutants can result in both upregulation and downregulation of transcript levels in *M. smegmatis*, depending on the gene. Upregulation of gene expression in RbpA mutants could be due to direct effects with RbpA acting as a repressor in some promoter contexts, due to differences in basal initiation kinetics. However, this observation could also be explained by indirect effects with RbpA enhancing the expression of a transcription factor that represses the expression of a set of genes. Future studies that expand analysis of RbpA past the limited promoters that have been explored *in vitro* will be necessary to address these possibilities.

Our data from spike-in control qRT-PCR experiments suggest that gene expression is globally downregulated in the *M. smegmatis* RbpA_{Mtb}⁷²⁻¹¹¹ mutant. This suggests that the NTT and CD are required for efficient gene expression, and it complicates interpretations of the RbpA_{Mtb}⁷²⁻¹¹¹ RNA-seq data in this study. This finding may also have an impact on a previously published RNA-seq data set for the *M. smegmatis* RbpA_{Mtb}⁷²⁻¹¹¹ strain (6). When we compared our RNA-seq data set for RbpA_{Mtb}⁷²⁻¹¹¹ with the previously reported data, we found that there was no significant overlap in genes that registered as upregulated or downregulated. This could be due to a difference in the culturing methods used in the two studies and/or it could be related to the finding that gene expression in general is less robust. How the NTT and CD mechanistically promote efficient gene expression while antagonizing RP_o stability on the *rrnAP3* promoter *in vitro* remains an open question for future studies.

MATERIALS AND METHODS

Media and bacterial strains. (i) *Mycobacterium tuberculosis*. The Erdman strain was grown at 37°C in 7H9 (broth) or 7H10 (agar) medium supplemented with 60 μ l/liter oleic acid, 5 g/liter bovine serum albumin (BSA), 2 g/liter dextrose, and 0.003 g/liter catalase (oleic acid-albumin-dextrose-catalase [OADC]), 0.5% glycerol, and 0.05% Tween 80 (broth). The *M. tuberculosis* merodiploid strain was constructed by integrating pMSG430-*rbpA*_{Mtb}^{WT} (expressing RbpA_{Mtb}^{WT} from a constitutive *Pmyc1-tetO* promoter; kanamycin resistant) into the *attB* site of the Erdman strain. A specialized transducing phage

with homology to *M. tuberculosis* H37Rv nucleotides 2307223 to 2307826 and 2303122 to 2308681 was used to replace all except the start and stop codons of the endogenous *rbpA* gene with a hygromycin resistance cassette in the merodiploid strain, thus generating $\Delta rbpA::tet-rbpA_{Mtb}^{WT}$. Gene swapping was used to construct strains of mycobacteria expressing different *rbpA* alleles and to test their viability, as described previously (13, 18). The *M. tuberculosis* $\Delta rbpA::tet-rbpA_{Mtb}^{WT}$ strain was transformed with pDB19-*rbpA_{Mtb}^{WT}* (expressing RbpA_{Mtb}^{WT} from a constitutive *Pmyc1-tetO* promoter; zeocin resistant) to replace the pMSG430-*rbpA_{Mtb}^{WT}* construct at the *attB* site of the *M. tuberculosis* $\Delta rbpA::tet-rbpA_{Mtb}^{WT}$ strain. The transformants were selected with zeocin, and loss of the pMSG430-*rbpA_{Mtb}^{WT}* construct was confirmed by verifying their inability to grow in the presence of kanamycin. The *M. tuberculosis* $\Delta rbpA::tet-rbpA_{Mtb}^{WT}$ strain transformed with pDB19-*rbpA_{Mtb}^{WT}* was named csm323. Csm323 was transformed with pMSG430-*rbpA_{Mtb}^{R79A}*, pMSG430-*rbpA_{Mtb}^{R88A}*, pMSG430-*rbpA_{Mtb}^{1-71}*, or pMSG430-*rbpA_{Mtb}^{72-111}* (expressing RbpA_{Mtb}^{R79A}, RbpA_{Mtb}^{R88A}, RbpA_{Mtb}¹⁻⁷¹, or RbpA_{Mtb}⁷²⁻¹¹¹, respectively, from a constitutive *Pmyc1-tetO* promoter; kanamycin resistant) to replace the pDB19-*rbpA_{Mtb}^{WT}* construct at the *attB* site of csm323. The transformants were selected with kanamycin; when positive transformants in *M. tuberculosis* csm323 could not be obtained (as was the case for pMSG430-*rbpA_{Mtb}^{R79A}*, pMSG430-*rbpA_{Mtb}^{R88A}*, pMSG430-*rbpA_{Mtb}^{1-71}*, and pMSG430-*rbpA_{Mtb}^{72-111}* transformations), the mutations were deemed nonviable.

(ii) ***Mycobacterium smegmatis***. All *M. smegmatis* strains were derived from mc²155 and grown at 37°C in LB medium supplemented with 0.5% dextrose, 0.5% glycerol, and 0.05% Tween 80 (broth). The *M. smegmatis* merodiploid strain was constructed by integrating pMSG430-*rbpA_{Mtb}^{WT}* into the *attB* site of mc²155. The *M. smegmatis* merodiploid strain was transformed with pDB88, with homology to mc²155 nucleotides 3928650 to 3929246 and 3929589 to 3930405, to replace the endogenous *rbpA*, using two-step allelic exchange as described previously (25), thus generating $\Delta rbpA::tet-rbpA_{Mtb}^{WT}$, which was named csm275. Csm275 was transformed with pDB19-*rbpA_{Mtb}^{WT}* to replace the pMSG430-*rbpA_{Mtb}^{WT}* construct at the *attB* site of the *M. smegmatis* $\Delta rbpA::tet-rbpA_{Mtb}^{WT}$ strain. The transformants were selected with zeocin, and loss of the pMSG430-*rbpA_{Mtb}^{WT}* construct was confirmed by verifying their inability to grow in the presence of kanamycin. The *M. smegmatis* $\Delta rbpA::tet-rbpA_{Mtb}^{WT}$ strain transformed with pDB19-*rbpA_{Mtb}^{WT}* was named csm291. Csm291 was transformed with pMSG430-*rbpA_{Mtb}^{WT}*, pMSG430-*rbpA_{Mtb}^{R79A}*, pMSG430-*rbpA_{Mtb}^{R88A}*, pMSG430-*rbpA_{Mtb}^{1-71}*, pMSG430-*rbpA_{Mtb}^{72-111}*, pMSG430-*rbpA_{Mtb}^{WT}-FLAG*, pMSG430-*rbpA_{Mtb}^{R79A}-FLAG*, pMSG430-*rbpA_{Mtb}^{R88A}-FLAG*, pMSG430-*rbpA_{Mtb}^{1-71}-FLAG*, or pMSG430-*rbpA_{Mtb}^{72-111}-FLAG* to replace the pDB19-*rbpA_{Mtb}^{WT}* construct at the *attB* site of csm291. Each FLAG tag repeated the sequence for FLAG twice (2×FLAG). The transformants were selected with kanamycin, and loss of the pDB19-*rbpA_{Mtb}^{WT}* construct was confirmed by verifying their inability to grow in the presence of zeocin. When positive transformants in csm291 could not be obtained (as was the case for pMSG430-*rbpA_{Mtb}^{1-71}* and pMSG430-*rbpA_{Mtb}^{1-71}-FLAG* transformations), the mutations were deemed nonviable. Csm291 strains transformed with pMSG430-*rbpA_{Mtb}^{R79A}*, pMSG430-*rbpA_{Mtb}^{R88A}*, pMSG430-*rbpA_{Mtb}^{72-111}*, pMSG430-*rbpA_{Mtb}^{WT}-FLAG*, pMSG430-*rbpA_{Mtb}^{R79A}-FLAG*, pMSG430-*rbpA_{Mtb}^{R88A}-FLAG*, and pMSG430-*rbpA_{Mtb}^{72-111}-FLAG* were named csm322, csm314, csm328, csm313, csm329, csm327, and csm347, respectively.

Antibiotics and chemicals. In mycobacterial cultures, 20 µg/ml kanamycin and 12.5 µg/ml zeocin were used. In *E. coli* cultures, 40 µg/ml kanamycin, 50 µg/ml chloramphenicol, 50 µg/ml streptomycin, and 100 µg/ml ampicillin were used.

Western blotting and immunoprecipitation. For immunoprecipitation, 1-liter cultures were pelleted by centrifugation, resuspended in 20 ml of 1× phosphate-buffered saline (PBS) with complete protease inhibitor cocktail (Roche), and lysed with high-pressure (30 lb/in²) cell disruption (CF model; Constant Systems, Daventry, UK). The lysate was treated with DNase I (New England BioLabs), added to anti-FLAG affinity gel (clone M2; Sigma-Aldrich, St. Louis, MO), and rotated overnight at 4°C. The protein-agarose matrix was washed three times with NP-40 buffer (10 mM sodium phosphate [pH 8.0], 150 mM NaCl, 1% Nonidet-40, 1× complete protease inhibitor cocktail). The immunoprecipitated protein complexes were eluted with 50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 150 µg/ml FLAG peptide (Sigma-Aldrich), 1× complete protease inhibitor cocktail. Protein samples were mixed with SDS-PAGE loading buffer and run on a 4 to 12% Bis-Tris protein gel (Invitrogen). For the Western blot analysis, σ^A and σ^B were detected using a mouse monoclonal antibody against *E. coli* σ^{70} (clone 2G10; Neoclone, Madison, WI), RNAP β was detected using a mouse monoclonal antibody against *E. coli* RNAP β (clone 8RB13; Neoclone), and FLAG-tagged RbpA was detected using an anti-FLAG mouse monoclonal antibody (Sigma-Aldrich). Secondary LiCor IRDye 800CW goat anti-mouse IgG polyclonal antibodies were used to detect the primary antibodies. Secondary antibody near-infrared fluorescence was detected with the LiCore Odyssey version 3.0 imaging system, and band intensity was analyzed with Image Studio Lite version 4.0.

Protein purification for biochemical assays. Plasmids containing the *Mycobacterium tuberculosis* H37Rv genomic DNA encoding the different *M. tuberculosis* RNAP holoenzyme subunits were a gift from Jayanta Mukhopadhyay (Bose Institute, Kolkata, India) (26, 27). Expression was carried out in accordance with the method described by Banerjee et al. (26), with minor exceptions. Briefly, *E. coli* BL21(DE3) cells were transformed with plasmids pET-Duet-*rpoB-rpoC* (encoding the β and β' subunits), pAcYc-Duet-*sigA-rpoA* (encoding an N-terminal 10×His-tagged σ^A subunit and α subunit), and pCDF-*rpoZ* (encoding the ω subunit) and were grown in LB medium at 37°C to an optical density at 600 nm (OD₆₀₀) of 0.6 to 0.8. The culture was then treated with 0.25 mM isopropyl- β -D-thiogalactopyranoside (IPTG) and grown overnight at 16°C. Cells were harvested via centrifugation (4,070 × *g* for 15 min at 4°C), and the resultant pellets were stored at -80°C. *M. tuberculosis* RNAP- σ^A holoenzyme was purified according to methods used previously for the *M. bovis* RNAP core complex (4). *M. tuberculosis* RbpA constructs were cloned into

pET-SUMO (Thermo Fisher Scientific) and transformed into *E. coli* BL21(DE3). Cultures were grown at 37°C to an OD₆₀₀ of 0.8, and protein overexpression was induced with the addition of 0.5 mM IPTG overnight at 16°C. Cells were harvested by centrifugation (4,070 × *g* for 15 min at 4°C), and the cell pellets were stored at –80°C. The cells were resuspended in lysis buffer (50 mM Na₂HPO₄ [pH 8.0], 5 mM imidazole, 300 mM NaCl, 5 mM β-mercaptoethanol, protease inhibitor [Sigma-Aldrich]) and lysed by sonication at 4°C. Soluble lysate was separated from insoluble lysate by centrifugation (2,700 × *g* for 20 min at 4°C). RbpA was purified from the soluble lysate by Ni²⁺ affinity chromatography (Gold Biotechnology). Ni²⁺ columns were washed with wash buffer (50 mM Na₂HPO₄ [pH 8.0], 20 mM imidazole, 300 mM NaCl) until no protein was detected with NanoDrop spectrophotometer OD₂₈₀ readings. RbpA was eluted from the Ni²⁺ affinity columns with elution buffer (50 mM Na₂HPO₄ [pH 8.0], 250 mM imidazole, 300 mM NaCl, 5 mM β-mercaptoethanol). The His-SUMO tag was cleaved from the RbpA constructs with His-Ulp1 protease during overnight dialysis at 4°C (20 mM Tris-HCl [pH 8.0], 250 mM NaCl, 20 mM imidazole, 1 mM β-mercaptoethanol). The His-SUMO tag and His-Ulp1 were separated from RbpA by a second round of Ni²⁺ affinity chromatography, and the cleaved RbpA was collected as the flowthrough fraction. Cleaved RbpA was dialyzed overnight at 4°C in storage buffer (20 mM Tris-HCl [pH 8.0], 250 mM NaCl, 1 mM β-mercaptoethanol), concentrated to approximately 200 μM (Vivaspin 20, molecular weight cutoff of 3,000; GE Healthcare), and stored at –80°C.

Preparation of fluorescent promoter DNA template. A Cy3-labeled promoter template of 150 bp +2 nontemplate dT, containing nucleotides 1470151 to 1470300 of the *M. tuberculosis* Erdman genomic DNA, including the *rrnAP3* promoter, was prepared as described previously (4, 7, 21).

Stopped-flow fluorescence assay. Stopped-flow experiments were performed as described previously (4, 7, 21), with notable exceptions. Prior to data acquisition, *M. tuberculosis* RNAP-σ^A holoenzyme, with or without RbpA protein, was incubated at 37°C for 10 min. All experiments were conducted with equal-volume mixing of 2 nM Cy3-labeled *rrnAP3* promoter DNA with 70 or 200 nM *M. tuberculosis* RNAP-σ^A holoenzyme, with or without 4 μM RbpA protein. Thus, the final concentrations upon mixing were 1 nM DNA and 35 or 100 nM RNAP-σ^A holoenzyme, with or without 2 μM RbpA protein. Accounting for all contributions from protein storage buffers, the final reaction buffer conditions upon equal-volume mixing were as follows: 20 mM Tris (pH 8.0), 77.5 mM NaCl, 10 mM MgCl₂, 5 μM ZnCl₂, 20 μM EDTA, 5% (vol/vol) glycerol, 1 mM dithiothreitol, and 0.1 mg/ml BSA. Experiments were performed with an SX-20 stopped-flow spectrophotometer (Applied Photophysics, Leatherhead, UK) with a dead time of ~1 ms and a total shot volume of ~100 μl. Samples were excited using a 535-nm fixed-wavelength light-emitting diode (LED) light source with a 550-nm shortpass filter, and emission was monitored using a 570-nm longpass filter. Data were collected at 37°C for 1,000 s by sampling 5,000 points over a logarithmic decay. Each protein condition is represented by the average of at least 5 shots obtained using multiple RNAP preparations, plotted as the fold change over DNA alone according to the formula $(F - F_o)/F_o$, where F_o is the buffer-subtracted reading for DNA alone and F is the buffer-subtracted reading for DNA mixed with protein.

RNA-seq analysis. *M. smegmatis* strains csm275, csm322, csm314, and csm328 were cultured to an OD₆₀₀ of 0.4 to 0.6, pelleted, resuspended in TRIzol (Thermo Fisher Scientific), and lysed by bead beating (FastPrep; MP Bio, Santa Ana, CA). RNA was extracted with chloroform, precipitated with isopropanol, and resuspended in water. RNA was treated with DNase I (Thermo Fisher Scientific), and RNA integrity and quality were analyzed with an Agilent bioanalyzer. rRNA was removed from samples using the Illumina Ribo-Zero rRNA removal kit. cDNA libraries were generated using an adapted Illumina TruSeq library preparation kit and were quality controlled by analysis of the cDNA size distribution with the Agilent TapeStation. cDNA libraries were pooled and sequenced in a single lane of an Illumina HiSeq 2000 Rapid Run flow cell with a 50-bp single-end read format. Sequencing reads were demultiplexed and converted to a FASTQ format using Illumina bcl2fastq script. Adapter sequences were trimmed from the raw reads, which were then aligned with the *M. smegmatis* mc²155 reference genome (GenBank accession number NC_008596) using the STAR aligner (28). Sequence alignment map (SAM) files generated from alignments were converted to BAM files using SAMTools (29), and aligned reads were counted per genome feature using the BioConductor package Subread featureCounts function (30). Differential expression analysis and subsequent PCA were performed with BioConductor DESeq2 (31). Venn diagrams were made with an online tool (<https://www.stefanjol.nl/venny>). Hypergeometric *P* values and enrichment values were calculated using an online calculator (<http://systems.crump.ucla.edu/hypergeometric>). The hypergeometric distribution describes the probability of *k* successes in *s* draws, without replacement, from a population of size *N* that contains exactly *M* successes. *N* was defined as the total number of differentially expressed genes in the two RbpA mutant constructs being compared, *s* was defined as the number of differentially upregulated or downregulated genes in one RbpA mutant included in the comparison, *M* was defined as the number of differentially upregulated or downregulated genes in the second RbpA mutant included in the comparison, and *k* was defined as the number of differentially upregulated or downregulated genes shared by the two RbpA mutants in the comparison.

qRT-PCR analysis. *M. smegmatis* strains csm275, csm322, csm314, and csm328 were cultured to an OD₆₀₀ of 0.5 to 0.7, pelleted, resuspended in TRIzol (Thermo Fisher Scientific), and lysed by bead beating (FastPrep; MP Bio). RNA was extracted with chloroform, precipitated with isopropanol, and resuspended in water. MS2 bacteriophage RNA (Roche) was added to the bacterial RNA at a ratio of 1 ng of MS2 RNA per 1 billion bacteria, RNA was treated with DNase I (Thermo Fisher Scientific), and cDNA was synthesized with the Superscript III first-strand synthesis system (Invitrogen). qRT-PCR was performed with a SYBR green qPCR kit (Bio-Rad), and MSMEG_0281, MSMEG_5302, MSMEG_1215, MSMEG_3966, MSMEG_3297, MSMEG_3499, MSMEG_3855, MSMEG_1680, MSMEG_2259, MSMEG_4222, MSMEG_2758, MSMEG_2528, MSMEG_4497, MSMEG_6466, MSMEG_6947, and MSMEG_2387 transcript levels were measured and

normalized to spike-in MS2 RNA transcript levels. Primers are listed in Table S3 in the supplemental material.

Accession number(s). The data discussed in this publication have been deposited in the NCBI Gene Expression Omnibus (32) and are accessible through GEO Series accession number [GSE107123](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107123).

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/JB.00690-17>.

SUPPLEMENTAL FILE 1, XLSX file, 2.0 MB.

SUPPLEMENTAL FILE 2, XLSX file, 0.1 MB.

SUPPLEMENTAL FILE 3, PDF file, 0.1 MB.

ACKNOWLEDGMENTS

C.L.S. and E.A.G. were supported by grant GM107544 from the NIH. C.L.S. was also supported by a Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Disease Award. J.P. and A.L.G. were supported by NIGMS grant GM007067. A.L.G. was also supported by a Stephen I. Morse Graduate Fellowship. G.S.-C. was supported by NIH grant R25HG006687. D.J. was supported by a Gary K. Ackers Fellowship and an Elliot L. Elson Education and Training Fellowship. J.J.M. was supported by NIH training grant AI007172-36A1. Purchase of the stopped-flow fluorescence equipment was made possible by equipment supplement 3R01GM107544-04S1 from the NIH. We thank the Genome Technology Access Center in the Department of Genetics at Washington University School of Medicine for help with genomic analysis; the center is partially supported by NCI Cancer Center Support grant P30CA91842 to Siteman Cancer Center and by ICTS/CTSA grant UL1TR000448 from the National Center for Research Resources, a component of the NIH, and the NIH Roadmap for Medical Research.

This publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the NIH.

REFERENCES

- World Health Organization. 2016. Global tuberculosis report 2016. World Health Organization, Geneva, Switzerland. <http://apps.who.int/iris/bitstream/handle/10665/250441/9789241565394-eng.pdf;jsessionid=428E77D20AE697AC55FF9BAE89B48DC5?sequence=1>.
- Calvori C, Frontali L, Leoni LTG. 1965. Effect of rifampicin on protein synthesis. *Nature* 207:417–418. <https://doi.org/10.1038/207417a0>.
- Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. *Cell* 104:901–912. [https://doi.org/10.1016/S0092-8674\(01\)00286-0](https://doi.org/10.1016/S0092-8674(01)00286-0).
- Rammohan J, Manzano AR, Garner AL, Stallings CL, Galbur EA. 2015. CarD stabilizes mycobacterial open complexes via a two-tiered kinetic mechanism. *Nucleic Acids Res* 43:3272–3285. <https://doi.org/10.1093/nar/gkv078>.
- Garner AL, Weiss LA, Manzano AR, Galbur EA, Stallings CL. 2014. CarD integrates three functional modules to promote efficient transcription, antibiotic tolerance, and pathogenesis in mycobacteria. *Mol Microbiol* 93:682–697. <https://doi.org/10.1111/mmi.12681>.
- Hubin EA, Fay A, Xu C, Bean JM, Glickman MS, Darst SA, Campbell EA. 2017. Structure and function of the mycobacterial transcription initiation complex with the essential regulator RbpA. *Elife* 6:e22520. <https://doi.org/10.7554/eLife.22520>.
- Rammohan J, Ruiz Manzano A, Garner AL, Prusa J, Stallings CL, Galbur EA. 2016. Cooperative stabilization of *Mycobacterium tuberculosis* *rrnAP3* promoter open complexes by RbpA and CarD. *Nucleic Acids Res* 44:7304–7313.
- Davis E, Chen J, Leon K, Darst SA, Campbell EA. 2015. Mycobacterial RNA polymerase forms unstable open promoter complexes that are stabilized by CarD. *Nucleic Acids Res* 43:433–445. <https://doi.org/10.1093/nar/gkv1231>.
- Stallings CL, Stephanou NC, Chu L, Hochschild A, Nickels BE, Glickman MS. 2009. CarD is an essential regulator of rRNA transcription required for *Mycobacterium tuberculosis* persistence. *Cell* 138:146–159. <https://doi.org/10.1016/j.cell.2009.04.041>.
- Verma AK, Chatterji D. 2014. Dual role of MsRbpA: transcription activation and rescue of transcription from the inhibitory effect of rifampicin. *Microbiology* 160:2018–2029. <https://doi.org/10.1099/mic.0.079186-0>.
- Bortoluzzi A, Muskett FW, Waters LC, Addis PW, Rieck B, Munder T, Schleier S, Forti F, Ghisotti D, Carr MD, O'Hare HM. 2013. *Mycobacterium tuberculosis* RNA polymerase-binding protein A (RbpA) and its interactions with sigma factors. *J Biol Chem* 288:14438–14450. <https://doi.org/10.1074/jbc.M113.459883>.
- Dey A, Verma AK, Chatterji D. 2011. Molecular insights into the mechanism of phenotypic tolerance to rifampicin conferred on mycobacterial RNA polymerase by MsRbpA. *Microbiology* 157:2056–2071. <https://doi.org/10.1099/mic.0.047480-0>.
- Weiss LA, Harrison PG, Nickels BE, Glickman MS, Campbell EA, Darst SA, Stallings CL. 2012. Interaction of CarD with RNA polymerase mediates *Mycobacterium tuberculosis* viability, rifampin resistance, and pathogenesis. *J Bacteriol* 194:5621–5631. <https://doi.org/10.1128/JB.00879-12>.
- Paget MSB, Molle V, Cohen G, Aharonowitz Y, Buttner MJ. 2001. Defining the disulphide stress response in *Streptomyces coelicolor* A3(2): identification of the σ^B regulon. *Mol Microbiol* 42:1007–1020. <https://doi.org/10.1046/j.1365-2958.2001.02675.x>.
- Tabib-Salazar A, Liu B, Doughty P, Lewis RA, Ghosh S, Parsy ML, Simpson PJ, O'Dwyer K, Matthews SJ, Paget MS. 2013. The actinobacterial transcription factor RbpA binds to the principal sigma subunit of RNA polymerase. *Nucleic Acids Res* 41:5679–5691. <https://doi.org/10.1093/nar/gkt277>.
- Hubin EA, Tabib-Salazar A, Humphrey LJ, Flack JE, Olinares PDB, Darst SA, Campbell EA, Paget MS. 2015. Structural, functional, and genetic analyses of the actinobacterial transcription factor RbpA. *Proc Natl Acad Sci U S A* 112:7171–7176. <https://doi.org/10.1073/pnas.1504942112>.
- Boyaci H, Chen J, Lilic M, Palka M, Mooney RA, Landick R, Darst SA, Campbell EA. 2018. Fidaxomicin jams *Mycobacterium tuberculosis* RNA polymerase motions needed for initiation via RbpA contacts. *Elife* 7:e34823. <https://doi.org/10.7554/eLife.34823>.
- Pashley CA, Parish T. 2003. Efficient switching of mycobacteriophage L5-

- based integrating plasmids in *Mycobacterium tuberculosis*. FEMS Microbiol Lett 229:211–215. [https://doi.org/10.1016/S0378-1097\(03\)00823-1](https://doi.org/10.1016/S0378-1097(03)00823-1).
19. Gonzalez-y-Merchand JA, Colstoni MJ, Cox RA. 1996. The rRNA operons of *Mycobacterium smegmatis* and *Mycobacterium tuberculosis*: comparison of promoter elements and of neighbouring upstream genes. Microbiology 142:667–674. <https://doi.org/10.1099/13500872-142-3-667>.
 20. Ko J, Heyduk T. 2014. Kinetics of promoter escape by bacterial RNA polymerase: effects of promoter contacts and transcription bubble collapse. Biochem J 463:135–144. <https://doi.org/10.1042/BJ20140179>.
 21. Garner AL, Rammohan J, Huynh JP, Onder LM, Chen J, Bae B, Jensen D, Weiss LA, Ruiz Manzano A, Darst SA, Campbell EA, Nickels BE, Galburt EA, Stallings CL. 2017. Effects of increasing the affinity of CarD for RNA polymerase on *Mycobacterium tuberculosis* growth, rRNA transcription, and virulence. J Bacteriol 199:e00698-16. <https://doi.org/10.1128/JB.00698-16>.
 22. Albery WJ, Knowles JR. 1976. Evolution of enzyme function and the development of catalytic efficiency. Biochemistry 15:5631–5640. <https://doi.org/10.1021/bi00670a032>.
 23. Chen K, Hu Z, Xia Z, Zhao D, Li W, Tyler JK. 2016. The overlooked fact: fundamental need for spike-in control for virtually all genome-wide analyses. Mol Cell Biol 36:662–667. <https://doi.org/10.1128/MCB.00970-14>.
 24. Raju RM, Unnikrishnan M, Rubin DHF, Krishnamoorthy V, Kandror O, Akopian TN, Goldberg AL, Rubin EJ. 2012. *Mycobacterium tuberculosis* ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection. PLoS Pathog 8:e1002511. <https://doi.org/10.1371/journal.ppat.1002511>.
 25. Barkan D, Stallings CL, Glickman MS. 2011. An improved counterselectable marker system for mycobacterial recombination using *galK* and 2-deoxy-galactose. Gene 470:31–36. <https://doi.org/10.1016/j.gene.2010.09.005>.
 26. Banerjee R, Rudra P, Prajapati RK, Sengupta S, Mukhopadhyay J. 2014. Optimization of recombinant *Mycobacterium tuberculosis* RNA polymerase expression and purification. Tuberculosis 94:397–404. <https://doi.org/10.1016/j.tube.2014.03.008>.
 27. Banerjee R, Rudra P, Saha A, Mukhopadhyay J. 2015. Recombinant reporter assay using transcriptional machinery of *Mycobacterium tuberculosis*. J Bacteriol 197:646–653. <https://doi.org/10.1128/JB.02445-14>.
 28. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. 2013. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29:15–21. <https://doi.org/10.1093/bioinformatics/bts635>.
 29. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. 2009. The sequence alignment/map format and SAMtools. Bioinformatics 25:2078–2079. <https://doi.org/10.1093/bioinformatics/btp352>.
 30. Liao Y, Smyth GK, Shi W. 2014. FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30:923–930. <https://doi.org/10.1093/bioinformatics/btt656>.
 31. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. <https://doi.org/10.1186/s13059-014-0550-8>.
 32. Edgar R. 2002. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30:207–210.